Prestige Consumer Healthcare (NYSE:PBH) Upgraded to “Buy” at DA Davidson

DA Davidson upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a neutral rating to a buy rating in a report published on Friday, Marketbeat reports. DA Davidson currently has $93.00 price target on the stock, up from their previous price target of $65.00.

PBH has been the subject of several other reports. StockNews.com downgraded shares of Prestige Consumer Healthcare from a strong-buy rating to a buy rating in a report on Tuesday, May 21st. Canaccord Genuity Group reaffirmed a buy rating and issued a $80.00 price objective on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $98.25.

Prestige Consumer Healthcare Trading Up 6.3 %

Shares of PBH stock opened at $69.37 on Friday. The company has a 50 day moving average of $67.16 and a 200-day moving average of $66.30. The company has a quick ratio of 2.02, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. Prestige Consumer Healthcare has a 12-month low of $56.34 and a 12-month high of $75.31. The firm has a market cap of $3.46 billion, a P/E ratio of 16.64, a PEG ratio of 1.84 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by ($0.12). The company had revenue of $277.00 million for the quarter, compared to analysts’ expectations of $287.42 million. Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.07 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PBH. GAMMA Investing LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at $25,000. Pacer Advisors Inc. boosted its holdings in Prestige Consumer Healthcare by 85.7% in the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after purchasing an additional 204 shares during the period. Principal Securities Inc. bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after acquiring an additional 208 shares during the last quarter. Finally, ORG Partners LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $36,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.